The complete Q3 report will be published on November 13, 2002.
The teleconference planned for November 8 at CET 11.00, will be moved forward to November 13, at the same time, please see separate announcement.
Lund den November 8, 2002
Active Biotech AB (Publ)
Sven Andréasson
President & CEO
Contacts:
Sven Andréasson, President & CEO, tel.: +46 46 19 20 49,
sven.andreasson@activebiotech.com
Cecilia Hofvander, Manager Corporate Communication, tel.: +46 46 19 11 22,
cecilia.hofvander@activebiotech.com
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. The company has a strong R&D portfolio and pipeline products focusing primarily on autoimmune/ inflammatory diseases and cancer. The lead projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat multiple sclerosis (SAIK), as well as a novel concept for use in cancer immunotherapy (TTS).
Active Biotech AB
Box 724,
SE-220 07 Lund
Sweden
Tel.: +46 46 19 20 00
Fax: +46 46 19 20 50
e-mail: info@activebiotech.com